Navigation Links
Myriad Genetics Presents Azixa's Mode of Action at AACR

s essential to its ability to inhibit tumor growth. It is believed that Azixa selectively disrupts tumor vasculature by inhibiting the formation of microtubules. Tumors rely on microtubules to maintain the cytoskeletal structure of their new vasculature, whereas mature vascular endothelium of healthy tissue uses actin filaments to provide the needed structure. Therefore, tumor vasculature is selectively targeted, leaving healthy normal tissue unaffected.

Azixa is currently being evaluated in two Phase 2 human clinical trials, one in patients with primary brain cancer and the other in melanoma that has spread to the brain.

Azixa is a trademark of Myriad Genetics, Inc. in the U.S. and other countries.

Myriad Genetics, Inc. is a biopharmaceutical company focused on the development of novel healthcare products. The Company develops and markets predictive medicine products, and is developing and intends to market therapeutic products. Myriad's news and other information are available on the Company's Web site at www.myriad.com.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements relating the potential for Azixa to treat cancer of several different types. These risks and uncertainties include, but are not limited to, our inability to further identify, develop and achieve commercial success for new products and technologies; our ability to discover drugs that are safer and more efficacious than our competitors; our ability to develop molecular diagnostic products that help assess which patients are subject to greater risk of developing diseases and who would therefore benefit from new preventive therapies; the possibility of delays in the research and development necessary to select drug development candidates and delays in clinical trials; the risk that clinica
'"/>




Page: 1 2 3

Related medicine technology :

1. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
2. Myriad Genetics Presents Tumor Origin Technology at AACR
3. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
4. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
5. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
6. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
7. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
8. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
9. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
10. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
11. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Myriad Genetics Presents Azixa Mode Action AACR
(Date:8/21/2014)... 2014  The board of directors of VirtualScopics, Inc. ... clinical trial imaging solutions, today announced that James ... effective immediately.  Mr. Groff has held the role of ... VirtualScopics in January 2006 as an accounting manager and ... "When the board of VirtualScopics asked Jim to assume ...
(Date:8/21/2014)... 21, 2014 /CNW/ - Bedrocan Cannabis Corp., previously Bedrocan ... to its Board of Directors, enhancing executive oversight ... company, a leading licensed producer of medicinal cannabis ... has 13 years, experience in producing and supplying ... including Canada. As previously announced ...
(Date:8/21/2014)... 2014  Cyberonics, Inc. (NASDAQ: CYBX ) today ... Quarterly highlights 1   Operating results ... first quarter of fiscal 2014, and other achievements, include: ... of 6.8%; , Strong international net sales of $13.2 ... , U.S. net product sales reached a new high ...
Breaking Medicine Technology:VirtualScopics, Inc. Names James Groff Chief Financial Officer 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 4Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16
... 20, 2010 ... ... --> ... // Results are keyed by longUrl, so we need to grab the first one. for (var r in data.results) ...
... Beaumont Hospitals, world renowned heart center has expanded and ... the new Ernst Cardiovascular Center at Beaumont Hospital, Royal ... Cardiovascular Center offer breakthrough surgeries and treatments for people ... also the new home for Beaumont,s innovative "7 tests ...
Cached Medicine Technology:Cipla Launches the World's First Generic Pirfenidone in India, Giving Hope to Sufferers of IPF (Idiopathic Pulmonary Fibrosis) 2Cipla Launches the World's First Generic Pirfenidone in India, Giving Hope to Sufferers of IPF (Idiopathic Pulmonary Fibrosis) 3Cipla Launches the World's First Generic Pirfenidone in India, Giving Hope to Sufferers of IPF (Idiopathic Pulmonary Fibrosis) 4Cipla Launches the World's First Generic Pirfenidone in India, Giving Hope to Sufferers of IPF (Idiopathic Pulmonary Fibrosis) 5Cipla Launches the World's First Generic Pirfenidone in India, Giving Hope to Sufferers of IPF (Idiopathic Pulmonary Fibrosis) 6Cipla Launches the World's First Generic Pirfenidone in India, Giving Hope to Sufferers of IPF (Idiopathic Pulmonary Fibrosis) 7Cipla Launches the World's First Generic Pirfenidone in India, Giving Hope to Sufferers of IPF (Idiopathic Pulmonary Fibrosis) 8Beaumont Hospital Opens New Ernst Cardiovascular Center 2
(Date:8/21/2014)... 21, 2014 The costs paid by consumers ... rise, according to insurer data. The Quotes Pros company is ... time using its tools at http://quotespros.com . , ... homepage connects with providers offering multiple coverage packages for dental ... to the public are now easier to compare using the ...
(Date:8/21/2014)... Today, Zane Benefits, the #1 Online Health ... credits in 2015. , According to Zane Benefits, premium ... Affordable Care Act (ACA), premium tax credits are available ... through the Health Insurance Marketplaces. , The new article ... of the tax credits, updated for 2015. , ...
(Date:8/21/2014)... Calcium buildup in the coronary arteries of chronic kidney ... disease risk, according to a new study in the ... ( JASN ). Researchers at the Johns Hopkins Bloomberg ... two other commonly used measures of subclinical atherosclerosis in ... kidney disease. , Approximately 50 percent of all patients ...
(Date:8/21/2014)... University of Texas MD Anderson Cancer Center today announced ... specialized breast screening at a network of community breast ... in late November, MD Anderson will become the exclusive ... Memorial Hermann,s 10 breast care centers, located in Memorial ... Over time, the network will expand to Memorial Hermann,s ...
(Date:8/21/2014)... Aug. 21, 2014 (HealthDay News) -- Not only is eating ... save them hundreds of health-care dollars a year, a new ... professor of public health sciences at Wake Forest Baptist Medical ... and obese type 2 diabetes patients. Participants ... assigned to either an intensive "lifestyle change program" focused on ...
Breaking Medicine News(10 mins):Health News:Dental Insurance Now Quoted for Families Online at Insurer Portal 2Health News:Measuring calcium buildup to predict heart disease in those with chronic kidney disease 2Health News:MD Anderson and Memorial Hermann to operate breast screening network across Houston area 2Health News:Getting Healthier a Big Money-Saver for People With Diabetes 2
... Sciton introduces ProLipo,PLUS(TM), an FDA-cleared, minimally invasive, ... fat, resulting in collagen remodeling and,tissue tightening. ... wavelengths in,one laser for optimal body sculpting results. ... it can also be utilized as a standalone ...
... FOR CAREER OF SCIENTIFIC DISCOVERY IN MOLECULAR IMAGING , ... The Radiologic Society of North America (RSNA) honored Ralph Weissleder, ... recognition afforded annually to one scientist who has made original ... of research. Dr. Weissleder is Professor at Harvard Medical ...
... to qualified recipients , , ... honor 31 recipients of the 2008 UCB Family Epilepsy Scholarship(TM) at ... American Epilepsy Society Annual Meeting. The scholarship is awarded to ... seek personal growth through higher learning. , , ...
... Transcept Pharmaceuticals,Inc., a privately-held specialty pharmaceutical company, announced ... is scheduled to,participate at the RBC Capital Markets 2008 ... "Delivering Novel Drug Solutions: The Future of Drug,Delivery." ... December,11, 2008 at 1:30 PM Eastern Time. , ...
... Americans cut prescription costs without compromising drug safety , ... A collection of online educational materials are now ... the dangers of contaminated or counterfeit drugs. Unveiled ... is designed to help consumers ensure the safety of ...
... and Alternative Risk Transfer Capabilities Further Expand Company,s Specialty Offerings- , ... Partner Agents- , , WORCESTER, Mass., ... THG ), a leading super regional property and casualty company, announced ... Holdings, Inc. , , (Logo: ...
Cached Medicine News:Health News:Sciton Introduces ProLipo PLUS(TM), the Most Robust Laser-Assisted Lipolysis System Available 2Health News:VisEn Co-Founder Named Radiologic Society's 'Outstanding Researcher of the Year' 2Health News:VisEn Co-Founder Named Radiologic Society's 'Outstanding Researcher of the Year' 3Health News:Unique Scholarship Helps People Affected by Epilepsy Fulfill Life Ambitions 2Health News:Unique Scholarship Helps People Affected by Epilepsy Fulfill Life Ambitions 3Health News:Unique Scholarship Helps People Affected by Epilepsy Fulfill Life Ambitions 4Health News:Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel 2Health News:Partnership for Safe Medicines Arms Public Against Counterfeit Drugs 2Health News:Partnership for Safe Medicines Arms Public Against Counterfeit Drugs 3Health News:Partnership for Safe Medicines Arms Public Against Counterfeit Drugs 4Health News:The Hanover Insurance Group Completes Acquisition of AIX Holdings, Inc. 2Health News:The Hanover Insurance Group Completes Acquisition of AIX Holdings, Inc. 3
Its MicroPoint design and reference marks at 10, 50 and 100 L ensure accurate performance with a variety of multi-channel and single-channel pipettors....
... its wide orifice tip, the Finntip Wide ... suspensions and macromolecules like genomic DNA. This ... cell fragmentation. It is excellent for use ... model, the inside diameter of the orifice ...
For plaque coring...
Capillary section fits into a 0.3-mm well for accurate loading of sequencing gels...
Medicine Products: